ProNAi to Report Wolverine Phase 2 Interim Results on June 6th at ASCO

- ProNAi to hold Analyst & Investor Event at 7:00am CT on June 6^th -
- ProNAi to Present at Jefferies 2016 Healthcare Conference in New York on June 9^th –

VANCOUVER, May 18, 2016 /CNW/ - ProNAi Therapeutics, Inc. (NASDAQ: DNAI), a clinical-stage oncology company advancing novel targeted therapeutics for patients with cancer, today announced it will present interim results from the Wolverine Phase 2 trial of PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) on June 6^th at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO).

Analyst & Investor Event
ProNAi will host an Analyst and Investor Event on Monday, June 6, 2016 from 7:00 - 8:00am CT where the company will present an update on the PNT2258 development program, including interim results from the Wolverine Phase 2 trial. Presenters will include: Dr. Nick Glover, President and Chief Executive Officer, Dr. Barbara Klencke, Chief Development Officer, and Dr. Angie You, Chief Business & Strategy Officer and Head of Commercial. The event will take place in the Hyde Park A/CC11A event room at the Hyatt Regency McCormick Place located at 2233 S. Dr. Martin Luther King Jr. Dr., Chicago, Illinois. This event will be webcast live and will be accessible through the company's website at www.pronai.com. An archived replay of the webcast will also be available.

ASCO 2016 Poster Presentation
Title: A phase 2 study of PNT2258 in patients with relapsed or refractory (r/r) diffuse large B-cell lymphoma (DLBCL): An initial report from the Wolverine study
Trials in Progress Abstract: #TPS7577
Poster: #130b
Poster Session: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Date and Time: Monday, June 6, 2016, 8:00 – 11:30am CT
Location: McCormick Place, Event room: Hall A, 2301 S King Dr, Chicago, Illinois
Track: Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Presenter: Jason R. Westin, MD, MS, Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center
The poster will be available on June 6, 2016 on the company's website at www.pronai.com

Jefferies 2016 Healthcare Conference in New York, NY
Dr. Nick Glover, President and Chief Executive Officer of ProNAi, will present an overview of the company at the Jefferies 2016 Healthcare Conference, being held at the Grand Hyatt Hotel in New York, NY. The presentation is scheduled for 2:30pm (Eastern Time) on Thursday, June 9^th. A live webcast of the presentation will be accessible through the ProNAi website at www.pronai.com.  An archived replay of the presentation will also be available.

About ProNAi Therapeutics
ProNAi Therapeutics is a clinical-stage oncology company advancing novel targeted therapeutics for patients with cancer. ProNAi's lead product candidate, PNT2258, is designed to target cancers that overexpress BCL2, an important and validated oncogene known to be dysregulated in many types of cancer. ProNAi is evaluating PNT2258 in two Phase 2 trials: "Wolverine", a Phase 2 trial evaluating PNT2258 for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL); and "Brighton", a Phase 2 trial evaluating PNT2258 for the treatment of Richter's transformation. For more information, please visit www.pronai.com.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding ProNAi's anticipated clinical development and potential business development strategies. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to risks and uncertainties, including, among others, the risk that ProNAi may be unable to successfully develop and commercialize PNT2258 or any other future product candidates, PNT2258 may fail to demonstrate safety and efficacy or may not otherwise produce positive results, ProNAi may experience delays in clinical trials, including due to difficulties enrolling patients, ProNAi's third-party manufacturers may cause its supply of materials to become limited or interrupted or fail to be of satisfactory quantity or quality, ProNAi's cash resources may be insufficient to fund its current operating plans and it may be unable to raise additional capital when needed, ProNAi may be unable to obtain and enforce intellectual property protection for its technologies and product candidates and the other factors described under the heading "Risk Factors" set forth in ProNAi's filings with the Securities and Exchange Commission from time to time. ProNAi undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

SOURCE ProNAi Therapeutics Inc.

James Smith, Vice President, Corporate Affairs, ProNAi Therapeutics, 604.558.6545, [email protected]